| |
cTACE (n = 174)
|
DEB TACE (n = 76)
|
p
|
|---|
|
TACE treatment
|
mean ± SD (range)
|
mean ± SD (range)
| |
|
TACE sessions per patient (n)
|
4.00 ± 3.09 (1–18)
|
2.96 ± 1.79 (1–9)
|
<0.01
|
|
Total duration of TACE treatment (days)
|
217.4 ± 266.1
|
143.9 ± 171.5
|
0.01
|
|
Subsequent treatment
|
na
|
%
|
na
|
%
| |
|
None
|
105
|
60.3
|
48
|
63.2
|
0.54
|
|
Crossover to other type of TACE
| | | | |
0.41
|
|
Yes
|
27
|
15.5
|
15
|
19.7
| |
|
No
|
147
|
84.5
|
61
|
80.3
| |
|
SIRT
| | | | |
0.09
|
|
Yes
|
11
|
6.3
|
1
|
1.3
| |
|
No
|
163
|
93.7
|
75
|
98.7
| |
|
Local ablation
| | | | |
0.18
|
|
Yes
|
12
|
6.9
|
2
|
2.6
| |
|
No
|
162
|
93.1
|
74
|
97.4
| |
|
Surgery
| | | | |
0.46
|
|
Yes
|
5
|
2.9
|
1
|
1.3
| |
|
No
|
169
|
97.1
|
75
|
98.7
| |
|
Sorafenib
| | | | |
0.77
|
|
Yes
|
25
|
14.4
|
12
|
15.8
| |
|
No
|
149
|
85.6
|
64
|
84.2
| |
|
Other systemic therapy
| | | | |
0.70
|
|
Yes
|
31
|
17.8
|
12
|
15.8
| |
|
No
|
143
|
82.2
|
64
|
84.2
| |
|
Patients receiving ≥2 treatments
| | | | |
1.00
|
|
Yes
|
16
|
9.2
|
7
|
9.2
| |
|
No
|
158
|
90.8
|
69
|
90.8
| |
- TACE transarterial chemoembolization, SD standard deviation, SIRT selective internal radiotherapy
- aSome patients received ≥2 subsequent treatments; therefore, the total number of treatments is greater than the total number of patients
